Patents by Inventor Marta PASCUAL GILABERT

Marta PASCUAL GILABERT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER
    Publication number: 20210230150
    Abstract: The present invention relates to compounds of formula (I) for use in preventing and/or treating cancer.
    Type: Application
    Filed: July 1, 2019
    Publication date: July 29, 2021
    Inventors: Josep ROMA CASTANYER, Marta PASCUAL GILABERT, José SÁNCHEZ DE TOLEDO CODINA, Soledad GALLEGO MELCÓN, Patricia ZARZOSA MARTÍNEZ, Javier ALONSO FERNÁNDEZ, Sergio PÉREZ OZCÁRIZ, Cristina LÓPEZ GÓMEZ, Josep CASTELLS BOLIART
  • Compounds for the treatment of myotonic dystrophy
    Patent number: 10226467
    Abstract: The present invention relates to a compound of formula (I), provided that this compound is not caffeine, for use in the treatment of myotonic dystrophy type 1 and type 2. The present invention also relates to compositions comprising the compound of formula (I). The present invention further relates to new compounds which are dimers of compounds of formula (I).
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: March 12, 2019
    Assignees: Universitat de Valencia, Institut Quimic de Sarria Cets Fundacio Privada, Institut Univ. de Ciencia I Tecnologia, S.A.
    Inventors: Ruben Artero Allepuz, Josep Castells Boliart, José Ignacio Borrell Bilbao, Beatriz Llamusi Troísi, Ariadna Bargiela Schönbrunn, Piotr Konieczny, Marta Pascual Gilabert, Jordi Teixidó Closa, Roger Estrada Tejedor, Alejandro López González
  • Biocatalytic production of nucleoside analogues as active pharmaceutical ingredients
    Patent number: 10184142
    Abstract: A biocatalytic process for producing active pharmaceutical ingredients (APIs) or intermediates thereof, wherein those APIs or their intermediates are nucleoside analogues (NAs) of formula I and wherein said NAs are active as pharmaceutically relevant antivirals and anticancer medicaments, intermediates or prodrugs thereof.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: January 22, 2019
    Assignee: Plasmia Biotech, S.L.
    Inventors: Marta Pascual Gilabert, Victor Manuel Deroncelé Thomas, Rafael Montilla Arévalo
  • DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES
    Publication number: 20180066295
    Abstract: The invention relates to a new synthetic process for obtaining compounds of formula (I) from compounds of formula (II) by means of cytidine deaminase enzymes.
    Type: Application
    Filed: March 18, 2016
    Publication date: March 8, 2018
    Inventors: Sergio PÉREZ OZCÁRIZ, Marta PASCUAL GILABERT, Carmen María FERNÁNDEZ FERNÁNDEZ, Josep CASTELLS BOLIART, Javier ALONSO FERNÁNDEZ, Cristina LÓPEZ GÓMEZ
  • COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY
    Publication number: 20170312285
    Abstract: The present invention relates to a compound of formula (I), provided that this compound is not caffeine, for use in the treatment of myotonic dystrophy type 1 and type 2. The present invention also relates to compositions comprising the compound of formula (I). The present invention further relates to new compounds which are dimers of compounds of formula (I).
    Type: Application
    Filed: November 13, 2015
    Publication date: November 2, 2017
    Inventors: Ruben ARTERO ALLEPUZ, Josep CASTELLS BOLIART, José Ignacio BORRELL BILBAO, Beatriz LLAMUSI TROÍSI, Ariadna BARGIELA SCHÖNBRUNN, Piotr KONIECZNY, Marta PASCUAL GILABERT, Jordi TEIXIDÓ CLOSA, Roger ESTRADA TEJEDOR, Alejandro LÓPEZ GONZÁLEZ
  • CAFFEINE FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 AND TYPE 2
    Publication number: 20170304309
    Abstract: The present invention relates to caffeine for use in the treatment of myotonic dystrophy type 1 and type 2. The present invention also relates to compositions comprising caffeine for use in the treatment of myotonic dystrophy type 1 and type 2.
    Type: Application
    Filed: November 13, 2015
    Publication date: October 26, 2017
    Inventors: Ruben ARTERO ALLEPUZ, Josep CASTELLS BOLIART, José Ignacio BORRELL BILBAO, Beatriz LLAMUSI TROÍSI, Ariadna BARGIELA SCHÖNBRUNN, Piotr KONIECZNY, Marta PASCUAL GILABERT, Jordi TEIXIDÓ CLOSA, Roger ESTRADA TEJEDOR, Alejandro LÓPEZ GONZÁLEZ
  • ENZYMATIC PRODUCTION OF CYTOSINIC NUCLEOSIDE ANALOGUES
    Publication number: 20160312261
    Abstract: The invention relates to the enzymatic production of cytosinic nucleoside analogues. In particular it relates to a new synthesis process of cytosine nucleoside analogues by using nucleoside phosphorylase enzymes, particularly Pyrimidin Nucleoside Phosphorylases (PyNPs) or mixtures of Purine Nucleoside Phosphorylases (PNPs) and PyNPs.
    Type: Application
    Filed: April 24, 2015
    Publication date: October 27, 2016
    Inventors: Marta PASCUAL GILABERT, Victor M. Deroncelé Thomas, Rafael Montilla Arévalo
  • BIOCATALYTIC PRODUCTION OF NUCLEOSIDE ANALOGUES AS ACTIVE PHARMACEUTICAL INGREDIENTS
    Publication number: 20160076070
    Abstract: A biocatalytic process for producing active pharmaceutical ingredients (APIs) or intermediates thereof, wherein those APIs or their intermediates are nucleoside analogues (NAs) of formula I and wherein said NAs are active as pharmaceutically relevant antivirals and anticancer medicaments, intermediates or prodrugs thereof.
    Type: Application
    Filed: April 29, 2014
    Publication date: March 17, 2016
    Inventors: Marta PASCUAL GILABERT, Victor Manuel DERONCELÉ THOMAS, Rafael MONTILLA ARÉVALO
  • -substituted--phenylethylsulfonamides for the identification of biological and pharmacological activity
    Patent number: 8809584
    Abstract: Novel compounds are continually sought after to treat and prevent diseases and disorders. The invention relates to N-substituted-N-phenylethylsulfonamides useful for being biologically and pharmacologically screened, and to contribute to the exploration and identification of new lead molecules that are capable of modulating the functional activity of a biological target.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: August 19, 2014
    Assignee: Institut Univ. de Ciencia i Tecnologia, S.A.
    Inventors: Josep Castells Boliart, David Enrique Miguel Centeno, Marta Pascual Gilabert
  • Thermostable biocatalyst combination for nucleoside synthesis
    Patent number: 8759034
    Abstract: A recombinant expression vector comprising: a) the sequence encoding a purine nucleoside phosphorylase (PNPase, E. C. 2.4.2.1), b) the sequence encoding a uridine phosphorylase (UPase, E. C. 2.4.2.3), c) or both; each of the sequences operably linked to one or more control sequences that direct the production of said phosphorylases in a suitable expression host; said sequences originating from the Archaea Thermoprotei class, characterized in that the PNPase is from Sulfolobus solfataricus (SEQ ID NO. 7) and the UPase is from Aeropyrum pernix (SEQ ID NO. 8). In addition, the present invention relates to A transglycosylation method between a sugar-donating nucleoside and an acceptor base in the presence of phosphate ions, characterized in that said method comprises the use of a uridine phosphorylase (UPase) of Aeropyrum pernix (NC_000854.2), a purine nucleoside phosphorylase (PNpase) of Sulfolobus solfataricus (NC_002754.1), or a combination thereof.
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: June 24, 2014
    Assignee: Plasmia Biotech, S.L.
    Inventors: Rafael Montilla Arevalo, Victor Manuel DeronceléThomas, Cristina López Gómez, Marta Pascual Gilabert, Carlos Estevez Company, Josep Castells Boliart
  • THERMOSTABLE BIOCATALYST COMBINATION FOR NUCLEOSIDE SYNTHESIS
    Publication number: 20130337547
    Abstract: A recombinant expression vector comprising: a) the sequence encoding a purine nucleoside phosphorylase (PNPase, E. C. 2.4.2.1), b) the sequence encoding a uridine phosphorylase (UPase, E. C. 2.4.2.3), c) or both; each of the sequences operably linked to one or more control sequences that direct the production of said phosphorylases in a suitable expression host; said sequences originating from the Archaea Thermoprotei class, characterized in that the PNPase is from Sulfolobus solfataricus (SEQ ID NO. 7) and the UPase is from Aeropyrum pernix (SEQ ID NO. 8). In addition, the present invention relates to A transglycosylation method between a sugar-donating nucleoside and an acceptor base in the presence of phosphate ions, characterised in that said method comprises the use of a uridine phosphorylase (UPase) of Aeropyrum pernix (NC_000854.2), a purine nucleoside phosphorylase (PNpase) of Sulfolobus solfataricus (NC_002754.1), or a combination thereof.
    Type: Application
    Filed: July 22, 2013
    Publication date: December 19, 2013
    Inventors: Rafael Montilla Arevalo, Victor Manuel Deroncelé Thomas, Cristina López Gómez, Marta Pascual Gilabert, Carlos Estevez Company, Josep Castells Boliart
  • -(2-oxo-1-phenylpiperidin-3-yl)sulfonamides for the identification of biological and pharmacological activity
    Patent number: 8569507
    Abstract: Novel compounds are continually sought after to treat and prevent diseases and disorders. The invention relates to N-(2-oxo-1-phenylpiperidin-3-yl)sulfonamides useful for being biologically and pharmacologically screened, and to contribute to the exploration and identification of new lead molecules that are capable of modulating the functional activity of a biological target.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: October 29, 2013
    Assignee: Institut Univ. De Ciencia I Technologia, S.A.
    Inventors: Josep Castells Boliart, David Enrique Miguel Centeno, Marta Pascual Gilabert
  • Thermostable biocatalyst combination for nucleoside synthesis
    Patent number: 8512997
    Abstract: The present invention relates to a recombinant expression vector comprising: a) the sequence encoding a purine nucleoside phosphorylase (PNPase, E. C. 2.4.2.1), b) the sequence encoding a uridine phosphorylase (UPase, E. C. 2.4.2.3), c) or both; each of the sequences operably linked to one or more control sequences that direct the production of said phosphorylases in a suitable expression host; said sequences originating from the Archaea Thermoprotei class, characterized in that the PNPase is from Sulfolobus solfataricus (SEQ ID NO. 7) and the UPase is from Aeropyrum pernix (SEQ ID NO. 8). In addition, the present invention relates to A transglycosylation method between a sugar-donating nucleoside and an acceptor base in the presence of phosphate ions, characterised in that said method comprises the use of a uridine phosphorylase (UPase) of Aeropyrum pernix (NC_000854.2), a purine nucleoside phosphorylase (PN-Pase) of Sulfolobus solfataricus (NC_002754.1), or a combination thereof.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: August 20, 2013
    Assignee: Plasmia Biotech, S.L.
    Inventors: Rafael Montilla Arevalo, Víctor Manuel Deroncelé Thomas, Cristina López Gómez, Marta Pascual Gilabert, Carlos Estévez Company, Josep Castells Boliart
  • 1-(sulfonyl)--phenylpyrrolidine-2-carboxamides for the identification of biological and pharmacological activity
    Patent number: 8455660
    Abstract: Novel compounds are continually sought after to treat and prevent diseases and disorders. The invention relates to 1-(sulfonyl)-N-phenylpyrrolidine-2-carboxamides which are useful for being biologically and pharmacologically screened, and to contribute to the exploration and identification of new lead molecules that are capable of modulating the functional activity of a biological target.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: June 4, 2013
    Assignee: Institut Univ. de Ciencia i Tecnologia, S.A.
    Inventors: Josep Castells Boliart, David Enrique Miguel Centeno, Marta Pascual Gilabert
  • THERMOSTABLE BIOCATALYST COMBINATION FOR NUCLEOSIDE SYNTHESIS
    Publication number: 20120264175
    Abstract: The present invention relates to a recombinant expression vector comprising: a) the sequence encoding a purine nucleoside phosphorylase (PNPase, E. C. 2.4.2.1), b) the sequence encoding a uridine phosphorylase (UPase, E. C. 2.4.2.3), c) or both; each of the sequences operably linked to one or more control sequences that direct the production of said phosphorylases in a suitable expression host; said sequences originating from the Archaea Thermoprotei class, characterized in that the PNPase is from Sulfolobus solfataricus (SEQ ID NO. 7) and the UPase is from Aeropyrum pernix (SEQ ID NO. 8). In addition, the present invention relates to A transglycosylation method between a sugar-donating nucleoside and an acceptor base in the presence of phosphate ions, characterised in that said method comprises the use of a uridine phosphorylase (UPase) of Aeropyrum pernix (NC_000854.2), a purine nucleoside phosphorylase (PN-Pase) of Sulfolobus solfataricus (NC_002754.1), or a combination thereof.
    Type: Application
    Filed: December 22, 2010
    Publication date: October 18, 2012
    Inventors: Rafael Montilla Arevalo, Víctor Manuel Deroncelé, Cristina López Gómez, Marta Pascual Gilabert, Carlos Estévez Company, Josep Castells Boliart
  • N-SUBSTITUTED-N-PHENYLETHYLSULFONAMIDES FOR THE IDENTIFICATION OF BIOLOGICAL AND PHARMACOLOGICAL ACTIVITY
    Publication number: 20120149909
    Abstract: Novel compounds are continually sought after to treat and prevent diseases and disorders. The invention relates to N-substituted-N-phenylethylsulfonamides useful for being biologically and pharmacologically screened, and to contribute to the exploration and identification of new lead molecules that are capable of modulating the functional activity of a biological target.
    Type: Application
    Filed: December 21, 2011
    Publication date: June 14, 2012
    Inventors: Josep Castells Boliart, David Enrique Miguel Centeno, Marta Pascual Gilabert
  • 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES FOR THE IDENTIFICATION OF BIOLOGICAL AND PHARMACOLOGICAL ACTIVITY
    Publication number: 20120142936
    Abstract: Novel compounds are continually sought after to treat and prevent diseases and disorders. The invention relates to 1-(sulfonyl)-N-phenylpyrrolidine-2-carboxamides which are useful for being biologically and pharmacologically screened, and to contribute to the exploration and identification of new lead molecules that are capable of modulating the functional activity of a biological target.
    Type: Application
    Filed: December 21, 2011
    Publication date: June 7, 2012
    Inventors: Josep Castells Boliart, David Enrique Miguel Centeno, Marta Pascual Gilabert
  • N-(2-OXO-1-PHENYLPIPERIDIN-3-YL)SULFONAMIDES FOR THE IDENTIFICATION OF BIOLOGICAL AND PHARMACOLOGICAL ACTIVITY
    Publication number: 20120142930
    Abstract: Novel compounds are continually sought after to treat and prevent diseases and disorders. The invention relates to N-(2-oxo-1-phenylpiperidin-3-yl)sulfonamides useful for being biologically and pharmacologically screened, and to contribute to the exploration and identification of new lead molecules that are capable of modulating the functional activity of a biological target.
    Type: Application
    Filed: December 21, 2011
    Publication date: June 7, 2012
    Inventors: Josep CASTELLS BOLIART, David Enrique MIGUEL CENTENO, Marta PASCUAL GILABERT
  • LIBRARIES OF N-(2-OXO-1-PHENYLPIPERIDIN-3-YL)SULFONAMIDES FOR DRUG DISCOVERY
    Publication number: 20120129888
    Abstract: Novel compounds are continually sought after to treat and prevent disorders. The invention relates to N-(2-oxo-1-phenylpiperidin-3-yl)sulfonamides useful for contributing to the search and identification of new lead compounds which can modulate the functional activity of a biological target.
    Type: Application
    Filed: December 22, 2011
    Publication date: May 24, 2012
    Inventors: JOSEP CASTELLS BOLIART, David Enrique Miguel Centeno, Marta Pascual Gilabert
  • LIBRARIES OF N-SUBSTITUTED-N-PHENYLETHYLSULFONAMIDES FOR THE IDENTIFICATION OF BIOLOGICAL AND PHARMACOLOGICAL ACTIVITY
    Publication number: 20120122710
    Abstract: New compounds are continually sought after for the treatment and prevention of disorders. The invention relates to N-substituted-N-phenylethylsulfonamides which can be biologically and pharmacologically traced, in order to be used in the search for, and identification of, new lead compounds that can modulate the functional activity of a biological target.
    Type: Application
    Filed: December 29, 2011
    Publication date: May 17, 2012
    Inventors: Josep Castells Boliart, David Enrique Miguel Centeno, Marta Pascual Gilabert